Pub Date : 2020-03-01DOI: 10.3760/CMA.J.ISSN.1008-6706.2020.05.004
Lin Luo, Xiaoxiao Li, Minhong Jiang, Jingwan Xiang, Jinbiao Jiang
Objective To analyze and compare VP1 and VP4 genetic characteristics of human enterovirus 71(EV71) isolated from children with severe and mild hand-foot and mouth disease(HFMD). Methods EV71 strains isolated from severe HFMD patients (6 cases) and mild HFMD patients (6 cases) in Taizhou district, Zhejiang province were included during 2016.Total virus RNA was extracted by Viral RNA Mini Extraction Kit, and reverse transcription polymerase chain reaction(RT-PCR) was used to amplify the sequence of the VP1 and VP4 genes of EV71.And then the sequencing results were compared with those of A, B, C genotype reference EV71 strains from GenBank by nucleotide alignment and amino acid alignment analysis. Results There were no statistically significant differences in sex and age between the two groups(χ2=14.51, t=2.82, all P<0.05). The homogeneity between EV71 strains from severe patients and mild patients was 95.8%~99.6% and 99.1%~100.0% for VP1 nucleotide sequences and amino acid sequences, respectively, while 95.0%~99.9% and 99.0%~100.0% for VP4 nucleotide sequences and amino acid sequences, respectively.The twelve EV71 strains isolated from HFMD patients in Taizhou shared the highest identity with EV71-genotype C, especially genotype C4a.In addition, compared with the mild patients, three respective strains from severe HFMD patients showed mutations at the residue 170 in the VP1 protein(V→L), residue 293 in the VP1 protein(A→S) and residue 7 in the VP4 protein(T→A). Conclusion All EV71 strains isolated from severe and mild HFMD patients in Taizhou district share high homology of nucleotide and amino sequence, and all of them belong to subgenogroup C4a.The mutations in the VP1 and VP4 of EV71 might be related to HFMD disease severity. Key words: Hand-foot and mouth disease; Enterovirus 71; Genotype; Disease severity; Mutation
{"title":"Sequence analysis of VP1 and VP4 genes of enterovirus 71 strains isolated from children with severe and mild hand-foot and mouth disease","authors":"Lin Luo, Xiaoxiao Li, Minhong Jiang, Jingwan Xiang, Jinbiao Jiang","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.004","url":null,"abstract":"Objective \u0000To analyze and compare VP1 and VP4 genetic characteristics of human enterovirus 71(EV71) isolated from children with severe and mild hand-foot and mouth disease(HFMD). \u0000 \u0000 \u0000Methods \u0000EV71 strains isolated from severe HFMD patients (6 cases) and mild HFMD patients (6 cases) in Taizhou district, Zhejiang province were included during 2016.Total virus RNA was extracted by Viral RNA Mini Extraction Kit, and reverse transcription polymerase chain reaction(RT-PCR) was used to amplify the sequence of the VP1 and VP4 genes of EV71.And then the sequencing results were compared with those of A, B, C genotype reference EV71 strains from GenBank by nucleotide alignment and amino acid alignment analysis. \u0000 \u0000 \u0000Results \u0000There were no statistically significant differences in sex and age between the two groups(χ2=14.51, t=2.82, all P<0.05). The homogeneity between EV71 strains from severe patients and mild patients was 95.8%~99.6% and 99.1%~100.0% for VP1 nucleotide sequences and amino acid sequences, respectively, while 95.0%~99.9% and 99.0%~100.0% for VP4 nucleotide sequences and amino acid sequences, respectively.The twelve EV71 strains isolated from HFMD patients in Taizhou shared the highest identity with EV71-genotype C, especially genotype C4a.In addition, compared with the mild patients, three respective strains from severe HFMD patients showed mutations at the residue 170 in the VP1 protein(V→L), residue 293 in the VP1 protein(A→S) and residue 7 in the VP4 protein(T→A). \u0000 \u0000 \u0000Conclusion \u0000All EV71 strains isolated from severe and mild HFMD patients in Taizhou district share high homology of nucleotide and amino sequence, and all of them belong to subgenogroup C4a.The mutations in the VP1 and VP4 of EV71 might be related to HFMD disease severity. \u0000 \u0000 \u0000Key words: \u0000Hand-foot and mouth disease; Enterovirus 71; Genotype; Disease severity; Mutation","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"526-531"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42453835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-01DOI: 10.3760/CMA.J.ISSN.1008-6706.2020.05.010
Ai-ye Guo, Man-ping Wu, Q. Fang, Hong-chao Chen
Objective To explore the clinical significance of prealbumin(PA) and γ-glutamyltranspeptidase (γ-GT) detection in evaluation of hyperbilirubinemia in neonates at different stages. Methods From August 2017 to August 2018, 300 full-term delivery patients with neonatal hyperbilirubinemia were selected, including 210 early-stage neonates and 90 late-stage neonates.According to the severity of bilirubinemia, the patients were classified into mild group (50 cases), moderate group (150 cases), and severe group (100 cases). The blood levels of PA and γ-GT of each group were detected. Results The levels of PA and γ-GT in late neonates were (95.81±4.58)mg/L, (44.97±5.21)IU/L, respectively, which were significantly higher than those in early neonates [(94.77±6.32)mg/L, (53.88±6.32)IU/L](t=1.410, 11.767, P=0.160, 0.000). With the increase of bilirubin level, the blood PA level was gradually decreased(P<0.05). The blood γ-GT level of moderate and severe patients were significantly higher than that of mild ones (t=2.222, 2.020, P=0.027, 0.046). The blood levels of γ-GT and PA had no statistically significant differences between moderate patients and severe patients (t=0.712, 1.741; P=0.477, 0.083). The blood PA level of moderate and severe patients were significantly lower than that of mild patients (t=2.357, 3.277, P=0.019, 0.001). The serum PA levels had no statistically significant difference between severe patients and moderate patients (t=0.719, P=0.474); and the serum PA levels of severe and moderate patients were lower than that of mild patients (t=3.234, 2.117, P=0.001, 0.043). The serum γ-GT levels among the three groups had no statistically significant differences (severe vs.moderate: t=0.297, P=0.767; severe vs.mild: t=0.269, P=0.788; moderate vs.mild: t=0.013, P=0.989). Conclusion By detecting the levels of PA and γ-GT in neonatal hyperbilirubinemia in different periods, it can provide a reference for clinical judgment of the condition of the children, thus guiding clinical rational treatment. Key words: Prealbumin; γ-glutamyltranspeptidase; Hyperbilirubinemia; Neonatal; Diagnostic value; Full term; Bilirubin
{"title":"Effects of PA and γ-glutamyltranspeptidase on hyperbilirubinemia in neonates","authors":"Ai-ye Guo, Man-ping Wu, Q. Fang, Hong-chao Chen","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.010","url":null,"abstract":"Objective \u0000To explore the clinical significance of prealbumin(PA) and γ-glutamyltranspeptidase (γ-GT) detection in evaluation of hyperbilirubinemia in neonates at different stages. \u0000 \u0000 \u0000Methods \u0000From August 2017 to August 2018, 300 full-term delivery patients with neonatal hyperbilirubinemia were selected, including 210 early-stage neonates and 90 late-stage neonates.According to the severity of bilirubinemia, the patients were classified into mild group (50 cases), moderate group (150 cases), and severe group (100 cases). The blood levels of PA and γ-GT of each group were detected. \u0000 \u0000 \u0000Results \u0000The levels of PA and γ-GT in late neonates were (95.81±4.58)mg/L, (44.97±5.21)IU/L, respectively, which were significantly higher than those in early neonates [(94.77±6.32)mg/L, (53.88±6.32)IU/L](t=1.410, 11.767, P=0.160, 0.000). With the increase of bilirubin level, the blood PA level was gradually decreased(P<0.05). The blood γ-GT level of moderate and severe patients were significantly higher than that of mild ones (t=2.222, 2.020, P=0.027, 0.046). The blood levels of γ-GT and PA had no statistically significant differences between moderate patients and severe patients (t=0.712, 1.741; P=0.477, 0.083). The blood PA level of moderate and severe patients were significantly lower than that of mild patients (t=2.357, 3.277, P=0.019, 0.001). The serum PA levels had no statistically significant difference between severe patients and moderate patients (t=0.719, P=0.474); and the serum PA levels of severe and moderate patients were lower than that of mild patients (t=3.234, 2.117, P=0.001, 0.043). The serum γ-GT levels among the three groups had no statistically significant differences (severe vs.moderate: t=0.297, P=0.767; severe vs.mild: t=0.269, P=0.788; moderate vs.mild: t=0.013, P=0.989). \u0000 \u0000 \u0000Conclusion \u0000By detecting the levels of PA and γ-GT in neonatal hyperbilirubinemia in different periods, it can provide a reference for clinical judgment of the condition of the children, thus guiding clinical rational treatment. \u0000 \u0000 \u0000Key words: \u0000Prealbumin; γ-glutamyltranspeptidase; Hyperbilirubinemia; Neonatal; Diagnostic value; Full term; Bilirubin","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"555-558"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44031157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-01DOI: 10.3760/CMA.J.ISSN.1008-6706.2020.05.020
Zhongmei Li
Objective To investigate the clinical effect of intra-abdominal pressure monitoring on jejunal nutrition in critically ill patients. Methods From March 2017 to September 2018, 124 critically ill patients who needed early jejunal nutrition in ICU of our hospital were selected and randomly divided into observation group (63 cases) and control group (61 cases) according to the digital table.The observation group adjusted enteral nutrition according to IAP monitoring, while the control group was routinely observed and guided enteral nutrition.Intra-abdominal pressure was compared between the two groups.The changes of blood lactic acid, endotoxin and APACHE Ⅱ score were compared between the two groups. Results After treatment for 7 days and 14 days, the intra-abdominal pressure of the observation group[(14.28±2.36)mmHg, (12.08±1.78)mmHg] were lower than those of the control group [(16.05±2.55)mmHg and (15.21±2.11)mmHg] (t=4.013, 8.939, all P<0.05). After treatment for 14 days, the blood lactic acid, endotoxin, APACHE Ⅱ score in the observation group were (2.19±0.73)mmol/L, (0.71±0.21)U/L and (10.02±1.54), which were lower than those in the control group [(3.98±0.95)mmol/L, (0.92±0.23)U/L and (13.06±1.72)] (t=11.788, 5.313, 10.376, all P<0.05). The incidences of abdominal distension (9.52%) and gastric retention (7.94%) in the observation group were significantly lower than those in the control group (28.57%, 27.87%) (χ2=7.930, 8.437, all P<0.05). Conclusion Early jejunal nutrition under the monitoring of intra-abdominal pressure in critically ill patients can help to reduce intra-abdominal hypertension, promote the rehabilitation of patients, reduce the incidence of complications of jejunal nutrition and improve patients’ tolerance, which is worthy of clinical promotion. Key words: Enteral nutrition; Pressure; Abdominal cavity; Lactic acid; Endotoxins; APACHE Ⅱ score
{"title":"Clinical effect of intra-abdominal pressure monitoring on jejunal nutrition in critically ill patients","authors":"Zhongmei Li","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.020","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.020","url":null,"abstract":"Objective \u0000To investigate the clinical effect of intra-abdominal pressure monitoring on jejunal nutrition in critically ill patients. \u0000 \u0000 \u0000Methods \u0000From March 2017 to September 2018, 124 critically ill patients who needed early jejunal nutrition in ICU of our hospital were selected and randomly divided into observation group (63 cases) and control group (61 cases) according to the digital table.The observation group adjusted enteral nutrition according to IAP monitoring, while the control group was routinely observed and guided enteral nutrition.Intra-abdominal pressure was compared between the two groups.The changes of blood lactic acid, endotoxin and APACHE Ⅱ score were compared between the two groups. \u0000 \u0000 \u0000Results \u0000After treatment for 7 days and 14 days, the intra-abdominal pressure of the observation group[(14.28±2.36)mmHg, (12.08±1.78)mmHg] were lower than those of the control group [(16.05±2.55)mmHg and (15.21±2.11)mmHg] (t=4.013, 8.939, all P<0.05). After treatment for 14 days, the blood lactic acid, endotoxin, APACHE Ⅱ score in the observation group were (2.19±0.73)mmol/L, (0.71±0.21)U/L and (10.02±1.54), which were lower than those in the control group [(3.98±0.95)mmol/L, (0.92±0.23)U/L and (13.06±1.72)] (t=11.788, 5.313, 10.376, all P<0.05). The incidences of abdominal distension (9.52%) and gastric retention (7.94%) in the observation group were significantly lower than those in the control group (28.57%, 27.87%) (χ2=7.930, 8.437, all P<0.05). \u0000 \u0000 \u0000Conclusion \u0000Early jejunal nutrition under the monitoring of intra-abdominal pressure in critically ill patients can help to reduce intra-abdominal hypertension, promote the rehabilitation of patients, reduce the incidence of complications of jejunal nutrition and improve patients’ tolerance, which is worthy of clinical promotion. \u0000 \u0000 \u0000Key words: \u0000Enteral nutrition; Pressure; Abdominal cavity; Lactic acid; Endotoxins; APACHE Ⅱ score","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"601-604"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70008565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-01DOI: 10.3760/CMA.J.ISSN.1008-6706.2020.05.030
Jingyi Tian
Discussions are made on the etiology and pathogenesis, classification, stages, special prescriptions, special medicines, Chinese patent medicines and external treatment of traditional Chinese medicine.This paper reviews the treatment of infectious mononucleosis (IM) in children by integrated traditional Chinese and western medicine in recent years, and provides new ideas for clinical treatment of IM. Key words: Infectious mononucleosis; Medicine, Chinese traditional; Overview; Child
{"title":"Clinical research progress of integrated traditional Chinese and western medicine in the treatment of infectious mononuclear cell hypertrophy in children","authors":"Jingyi Tian","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.030","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.030","url":null,"abstract":"Discussions are made on the etiology and pathogenesis, classification, stages, special prescriptions, special medicines, Chinese patent medicines and external treatment of traditional Chinese medicine.This paper reviews the treatment of infectious mononucleosis (IM) in children by integrated traditional Chinese and western medicine in recent years, and provides new ideas for clinical treatment of IM. \u0000 \u0000Key words: \u0000Infectious mononucleosis; Medicine, Chinese traditional; Overview; Child","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"637-640"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43510061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-01DOI: 10.3760/CMA.J.ISSN.1008-6706.2020.05.017
Zhidi Li
Objective To investigate the clinical efficacy of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum B-type natriuretic peptide(BNP). Methods From December 2017 to February 2019, 102 patients with heart failure admitted to Lyucheng Cardiovascular Hospital of Zhejiang Province were selected and divided into control group and treatment group according to random number table method, with 51 cases in each group.The control group was treated with routine treatment, while the treatment group was treated with sakubattral and valsartan sodium tablets on the basis of routine treatment.Both two groups were treated for 12 weeks.The heart function[including left ventricular ejection fraction(LVEF), cardiac output per stroke(SV) and left ventricular end-diastolic diameter(LVEDD)], serum BNP, 6-minute walking distance(6MWD) and quality of life were compared between the two groups before and after treatment. Results The total effective rate of the treatment group was 94.12%(48/51), which was higher than 72.55%(37/51) of the control group, the difference was statistically significant(χ2=8.541, P<0.05). After treatment, the LVEF[(60.28±6.97)%] and SV[(78.91±4.23)mL] in the treatment group were higher than those in the control group[(52.31±4.56)% and (71.35±6.74)mL], while the LVEDD in the trentment group [(54.89±5.26)mm]was lower than that in the control group[(61.74±4.80)mm], the differences were statistically significant(t=6.834, 6.785, 6.870, all P<0.05). After treatment, the serum BNP level in the treatment group[(164.32±14.39)ng/L] was lower than that in the control group[(248.96±23.15)ng/L], while the 6MWD in the trentment group [(353.27±42.26)m] was higher than that in the control group[(273.21±34.47)m], the differences were statistically significant (t=22.175, 10.484, all P<0.05). After treatment, the MLHFQ score in the treatment group[(27.83±5.41)points] was lower than that in the control group[(41.98±7.64)points], the difference was statistically significant(t=10.794, P<0.05). Conclusion Sakubattral and valsartan sodium tablets has good clinical efficacy in treating heart failure, it can improve cardiac function and reduce serum BNP level, which is worthy of clinical application. Key words: Heart Failure; Sakubattral and valsartan sodium tablets; Heart function tests; Stroke volume; Natriuretic peptide, brain; Quality of Life
{"title":"Clinical observation of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum BNP level","authors":"Zhidi Li","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.017","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.017","url":null,"abstract":"Objective \u0000To investigate the clinical efficacy of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum B-type natriuretic peptide(BNP). \u0000 \u0000 \u0000Methods \u0000From December 2017 to February 2019, 102 patients with heart failure admitted to Lyucheng Cardiovascular Hospital of Zhejiang Province were selected and divided into control group and treatment group according to random number table method, with 51 cases in each group.The control group was treated with routine treatment, while the treatment group was treated with sakubattral and valsartan sodium tablets on the basis of routine treatment.Both two groups were treated for 12 weeks.The heart function[including left ventricular ejection fraction(LVEF), cardiac output per stroke(SV) and left ventricular end-diastolic diameter(LVEDD)], serum BNP, 6-minute walking distance(6MWD) and quality of life were compared between the two groups before and after treatment. \u0000 \u0000 \u0000Results \u0000The total effective rate of the treatment group was 94.12%(48/51), which was higher than 72.55%(37/51) of the control group, the difference was statistically significant(χ2=8.541, P<0.05). After treatment, the LVEF[(60.28±6.97)%] and SV[(78.91±4.23)mL] in the treatment group were higher than those in the control group[(52.31±4.56)% and (71.35±6.74)mL], while the LVEDD in the trentment group [(54.89±5.26)mm]was lower than that in the control group[(61.74±4.80)mm], the differences were statistically significant(t=6.834, 6.785, 6.870, all P<0.05). After treatment, the serum BNP level in the treatment group[(164.32±14.39)ng/L] was lower than that in the control group[(248.96±23.15)ng/L], while the 6MWD in the trentment group [(353.27±42.26)m] was higher than that in the control group[(273.21±34.47)m], the differences were statistically significant (t=22.175, 10.484, all P<0.05). After treatment, the MLHFQ score in the treatment group[(27.83±5.41)points] was lower than that in the control group[(41.98±7.64)points], the difference was statistically significant(t=10.794, P<0.05). \u0000 \u0000 \u0000Conclusion \u0000Sakubattral and valsartan sodium tablets has good clinical efficacy in treating heart failure, it can improve cardiac function and reduce serum BNP level, which is worthy of clinical application. \u0000 \u0000 \u0000Key words: \u0000Heart Failure; Sakubattral and valsartan sodium tablets; Heart function tests; Stroke volume; Natriuretic peptide, brain; Quality of Life","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"586-590"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48337348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-01DOI: 10.3760/CMA.J.ISSN.1008-6706.2020.05.011
Fang Dai, H. Shao
Objective To explore the efficacy and safety of Yinchenhao Decoction combined with blue light irradiation in the treatment of neonatal pathological jaundice. Methods From January 2018 to October 2018, a total of 94 neonates with pathological jaundice admitted to our hospital were divided into the control group and the observation group, with 47 cases in each group.On the basis of conventional treatment, the control group was given blue light irradiation treatment, while the observation group was treated with Yinchenhao Decoction on the basis of the control group.The changes of TBIL, UCB, TBA and HS-CRP levels, β-GD levels, clinical efficacy and incidence of adverse events were compared between the two groups after 7 days of treatment. Results After 7 days of treatment, the TBIL, UCB, TBA and HS-CRP levels in the observation group were (116.4±6.9)μmol/L, (153.6±8.2)μmol/L, (8.3±1.3)μmol/L, (4.9±0.6)mg/L, respectively, which were lower than those in the control group [(153.6±8.2)μmol/L, (249.3±42.3)μmol/L, (25.9±2.9)μmol/L, (18.3±0.5)mg/L] (t=15.851, 20.329, 9.624, 7.508, all P<0.05). The β-GD level reduced more significant in the observation group, which in both two groups were decreased after treatment (all P<0.05). The total effective rate of the observation group was 97.9%(46/47), which was significantly higher than that of the control group[85.1%(40/47)], and the total incidence of adverse reactions in the observation group was 4.3%(2/47), which was significantly lower than that in the control group[29.8%(17/47)], the differences were statistically significant(χ2=11.562, 14.605, all P<0.01). Conclusion Yinchenhao Decoction combined with blue light irradiation is effective in the treatment of neonatal pathological jaundice, possibly by affecting β-GD levels.In addition, it can significantly reduce the incidence of adverse reactions in children, with better efficacy and higher safety.It is worthy of clinical reference and promotion. Key words: Jaundice, neonatal; Drugs, Chinese herbal; Balneology; Color therapy; Bilirubin; Bile acids and salts; C-reactive protein; Aldehyde dehydrogenase; Comparative study
{"title":"Efficacy and safety of Yinchenhao Decoction combined with blue light irradiation in the treatment of neonatal pathological jaundice","authors":"Fang Dai, H. Shao","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.011","url":null,"abstract":"Objective \u0000To explore the efficacy and safety of Yinchenhao Decoction combined with blue light irradiation in the treatment of neonatal pathological jaundice. \u0000 \u0000 \u0000Methods \u0000From January 2018 to October 2018, a total of 94 neonates with pathological jaundice admitted to our hospital were divided into the control group and the observation group, with 47 cases in each group.On the basis of conventional treatment, the control group was given blue light irradiation treatment, while the observation group was treated with Yinchenhao Decoction on the basis of the control group.The changes of TBIL, UCB, TBA and HS-CRP levels, β-GD levels, clinical efficacy and incidence of adverse events were compared between the two groups after 7 days of treatment. \u0000 \u0000 \u0000Results \u0000After 7 days of treatment, the TBIL, UCB, TBA and HS-CRP levels in the observation group were (116.4±6.9)μmol/L, (153.6±8.2)μmol/L, (8.3±1.3)μmol/L, (4.9±0.6)mg/L, respectively, which were lower than those in the control group [(153.6±8.2)μmol/L, (249.3±42.3)μmol/L, (25.9±2.9)μmol/L, (18.3±0.5)mg/L] (t=15.851, 20.329, 9.624, 7.508, all P<0.05). The β-GD level reduced more significant in the observation group, which in both two groups were decreased after treatment (all P<0.05). The total effective rate of the observation group was 97.9%(46/47), which was significantly higher than that of the control group[85.1%(40/47)], and the total incidence of adverse reactions in the observation group was 4.3%(2/47), which was significantly lower than that in the control group[29.8%(17/47)], the differences were statistically significant(χ2=11.562, 14.605, all P<0.01). \u0000 \u0000 \u0000Conclusion \u0000Yinchenhao Decoction combined with blue light irradiation is effective in the treatment of neonatal pathological jaundice, possibly by affecting β-GD levels.In addition, it can significantly reduce the incidence of adverse reactions in children, with better efficacy and higher safety.It is worthy of clinical reference and promotion. \u0000 \u0000 \u0000Key words: \u0000Jaundice, neonatal; Drugs, Chinese herbal; Balneology; Color therapy; Bilirubin; Bile acids and salts; C-reactive protein; Aldehyde dehydrogenase; Comparative study","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"559-562"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48417182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-01DOI: 10.3760/CMA.J.ISSN.1008-6706.2020.05.007
Zhen Chen, J. Chen
Objective To investigate the alternate application efficacy of high-frequency oscillatory ventilation and constant-frequency mechanical ventilation in the treatment of premature infants with respiratory distress syndrome. Methods From April 2015 to August 2017, 174 premature infants with respiratory distress syndrome were chosen in this research and randomly divided into three groups.CF group was treated with constant-frequency mechanical ventilation, HF group was treated with high-frequency oscillatory ventilation, AP group was treated with alternate application of constant-frequency mechanical ventilation and high-frequency oscillatory ventilation.After treatment, the oxygen time, mechanical ventilation time, oxygenation, complications and survival in the three groups were compared. Results The oxygen time, mechanical ventilation time of the AP group were shorter than those of the HF group and the CF group, the differences were statistically significant (all P 0.05). Conclusion Alternate application of high-frequency oscillatory ventilation and constant-frequency mechanical ventilation in the treatment of premature infants with respiratory distress syndrome can improve oxygenation, shorten oxygen time and mechanical ventilation time, with good safety. Key words: Respiratory distress syndrome; Premature infants; Constant-frequency mechanical ventilation; High-frequency oscillatory ventilation
{"title":"Alternate application efficacy of high-frequency oscillatory ventilation and constant-frequency mechanical ventilation in the treatment of premature infants with respiratory distress syndrome","authors":"Zhen Chen, J. Chen","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.007","url":null,"abstract":"Objective \u0000To investigate the alternate application efficacy of high-frequency oscillatory ventilation and constant-frequency mechanical ventilation in the treatment of premature infants with respiratory distress syndrome. \u0000 \u0000 \u0000Methods \u0000From April 2015 to August 2017, 174 premature infants with respiratory distress syndrome were chosen in this research and randomly divided into three groups.CF group was treated with constant-frequency mechanical ventilation, HF group was treated with high-frequency oscillatory ventilation, AP group was treated with alternate application of constant-frequency mechanical ventilation and high-frequency oscillatory ventilation.After treatment, the oxygen time, mechanical ventilation time, oxygenation, complications and survival in the three groups were compared. \u0000 \u0000 \u0000Results \u0000The oxygen time, mechanical ventilation time of the AP group were shorter than those of the HF group and the CF group, the differences were statistically significant (all P 0.05). \u0000 \u0000 \u0000Conclusion \u0000Alternate application of high-frequency oscillatory ventilation and constant-frequency mechanical ventilation in the treatment of premature infants with respiratory distress syndrome can improve oxygenation, shorten oxygen time and mechanical ventilation time, with good safety. \u0000 \u0000 \u0000Key words: \u0000Respiratory distress syndrome; Premature infants; Constant-frequency mechanical ventilation; High-frequency oscillatory ventilation","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"541-545"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47157412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-01DOI: 10.3760/CMA.J.ISSN.1008-6706.2020.05.006
Rong-bo Jia
Objective To observe the effect of Xiaoerfeire Kechuan Granule in the treatment of bronchopneumonia in children and its effect on serum activating protein(APC) and interleukin-1 receptor(IL-1R). Methods From June 2016 to June 2018, 116 children with pediatric bronchial pneumonia admitted to the Maternal and Child Health Hospital of Lishui were selected as observation subjects.According to the random number table method, the patients were divided into observation group and control group, with 58 cases in each group.Both two groups were given conventional therapy.On the basis of this treatment, the observation group was treated with Xiaoerfeire Kechuan Granule.The therapeutic effects, the disappearance time of clinical symptoms, and the changes of APC and IL-1R levels before and after treatment were observed. Results After treatment, the total effective rate of the observation group was 96.55%, which was higher than that of the control group(81.03%), the difference was statistically significant(χ2=7.017, P=0.008). The defervescence time, lung voice disappeared time, disappearance time of X-ray inflammation and disappearance time of cough in the observation group were shorter than those in the control group, and the differences were statistically significant(t=9.134, 13.157, 3.407, 8.532, all P 0.05). After treatment, the serum ACP levels increased in both two groups(all P<0.05), and the ACP level of the observation group was higher than that of the control group(t=5.209, P<0.05); the serum IL-1R level of the two groups were decreased(all P<0.05), and the IL-1R level of the observation group was lower than that of the control group (t=11.835, P<0.05). Conclusion Xiaoerfeire Kechuan Granule is effective in the treatment of children with bronchopneumonia, which can improve the clinical symptoms of children rapidly, its mechanism may be related to lowering serum IL-1R level and increasing APC level. Key words: Xiaoerfeire Kechuan Granule; Bronchial pneumonia; Integrated Chinese and western medicine therapy; activating protein; IL-1R; Efficacy; Improve symptoms
{"title":"Effect of Xiaoerfeire Kechuan Granule in the treatment of children with bronchopneumonia and its effect on serum APC and IL-1R","authors":"Rong-bo Jia","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.006","url":null,"abstract":"Objective \u0000To observe the effect of Xiaoerfeire Kechuan Granule in the treatment of bronchopneumonia in children and its effect on serum activating protein(APC) and interleukin-1 receptor(IL-1R). \u0000 \u0000 \u0000Methods \u0000From June 2016 to June 2018, 116 children with pediatric bronchial pneumonia admitted to the Maternal and Child Health Hospital of Lishui were selected as observation subjects.According to the random number table method, the patients were divided into observation group and control group, with 58 cases in each group.Both two groups were given conventional therapy.On the basis of this treatment, the observation group was treated with Xiaoerfeire Kechuan Granule.The therapeutic effects, the disappearance time of clinical symptoms, and the changes of APC and IL-1R levels before and after treatment were observed. \u0000 \u0000 \u0000Results \u0000After treatment, the total effective rate of the observation group was 96.55%, which was higher than that of the control group(81.03%), the difference was statistically significant(χ2=7.017, P=0.008). The defervescence time, lung voice disappeared time, disappearance time of X-ray inflammation and disappearance time of cough in the observation group were shorter than those in the control group, and the differences were statistically significant(t=9.134, 13.157, 3.407, 8.532, all P 0.05). After treatment, the serum ACP levels increased in both two groups(all P<0.05), and the ACP level of the observation group was higher than that of the control group(t=5.209, P<0.05); the serum IL-1R level of the two groups were decreased(all P<0.05), and the IL-1R level of the observation group was lower than that of the control group (t=11.835, P<0.05). \u0000 \u0000 \u0000Conclusion \u0000Xiaoerfeire Kechuan Granule is effective in the treatment of children with bronchopneumonia, which can improve the clinical symptoms of children rapidly, its mechanism may be related to lowering serum IL-1R level and increasing APC level. \u0000 \u0000 \u0000Key words: \u0000Xiaoerfeire Kechuan Granule; Bronchial pneumonia; Integrated Chinese and western medicine therapy; activating protein; IL-1R; Efficacy; Improve symptoms","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"537-540"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41446285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Application value of visceral fat area in screening risk factors of diabetic nephropathy","authors":"Yanlong Hua, Lin Zhang","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.021","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.021","url":null,"abstract":"目的 \u0000探讨生物电阻抗法测定的内脏脂肪面积(VFA)在糖尿病肾病危险因素筛查中的应用价值及其与尿蛋白/肌酐比值(UACR)的关系。 \u0000 \u0000 \u0000方法 \u0000选取巴彦淖尔市医院2018年住院治疗的糖尿病患者60例，采用生物电阻抗法测定VFA，同时检测身体质量指数(BMI)、糖化血红蛋白(HbA1c)、UACR，分析VFA与UACR之间的关系。 \u0000 \u0000 \u0000结果 \u0000内脏肥胖患者UACR较非肥胖患者增高[(25.9±3.3)mg/g比(19.8±4.1)mg/g，t＝－3.871，P<0.05]。VFA与BMI对肥胖患病率评估差异有统计学意义[65%(39/60)比68%(41/60)，χ2＝18.100，P<0.05]。VFA与UACR有相关性(r＝0.470，P<0.05)。 \u0000 \u0000 \u0000结论 \u0000生物电阻抗法测定的VFA与UACR有相关性，可用于糖尿病肾病危险因素筛查。","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"605-607"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43510238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-01DOI: 10.3760/CMA.J.ISSN.1008-6706.2020.05.012
Gang Lou, L. Chi, Weili Chen, Zhenxiao Chai, K. Xia, Chao-quan Wu
Objective To explore the effect of dual antiplatelet combined with calf serum deproteinized injection in the treatment of mild ischemic stroke after intravenous thrombolysis. Methods From October 2017 to December 2018, 82 patients with mild ischemic stroke who were diagnosed in the People's Hospital of Ruian were selected.The patients were divided into control group (41 cases) and observation group (41 cases) according to random number table method.The control group was treated with aspirin after intravenous thrombolysis.On this basis, the observation group was treated with dual antiplatelet combined with calf serum deproteinized injection.The course of treatment was 3 months in both two groups.The total effective rate, the changes of hemorheological indicators, the improvement of neurological deficit, the ability of daily living and the ability of returning to society were compared between the two groups before and after treatment.The complications and prognosis were recorded. Results The total effective rate of the observation group was 95.12% (39/41), which was higher than 78.05% (32/41) of the control group (χ2=5.145, P 0.05). Conclusion After intravenous thrombolytic therapy for patients with mild ischemic stroke, dual antiplatelet therapy combined with calf serum deproteinized injection can improve the neurological function, life ability and hemorheological indicators of patients, with good prognosis, it is safe and effective. Key words: Stroke; Thrombolytic therapy; Aspirin; Platelet aggregation inhibitors; Calf serum deproteinized injection; Drug therapy, combination; Hemorheology; Prognosis
{"title":"Therapeutic effect of intravenous thrombolysis combined with drug therapy on mild ischemic stroke","authors":"Gang Lou, L. Chi, Weili Chen, Zhenxiao Chai, K. Xia, Chao-quan Wu","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.012","url":null,"abstract":"Objective \u0000To explore the effect of dual antiplatelet combined with calf serum deproteinized injection in the treatment of mild ischemic stroke after intravenous thrombolysis. \u0000 \u0000 \u0000Methods \u0000From October 2017 to December 2018, 82 patients with mild ischemic stroke who were diagnosed in the People's Hospital of Ruian were selected.The patients were divided into control group (41 cases) and observation group (41 cases) according to random number table method.The control group was treated with aspirin after intravenous thrombolysis.On this basis, the observation group was treated with dual antiplatelet combined with calf serum deproteinized injection.The course of treatment was 3 months in both two groups.The total effective rate, the changes of hemorheological indicators, the improvement of neurological deficit, the ability of daily living and the ability of returning to society were compared between the two groups before and after treatment.The complications and prognosis were recorded. \u0000 \u0000 \u0000Results \u0000The total effective rate of the observation group was 95.12% (39/41), which was higher than 78.05% (32/41) of the control group (χ2=5.145, P 0.05). \u0000 \u0000 \u0000Conclusion \u0000After intravenous thrombolytic therapy for patients with mild ischemic stroke, dual antiplatelet therapy combined with calf serum deproteinized injection can improve the neurological function, life ability and hemorheological indicators of patients, with good prognosis, it is safe and effective. \u0000 \u0000 \u0000Key words: \u0000Stroke; Thrombolytic therapy; Aspirin; Platelet aggregation inhibitors; Calf serum deproteinized injection; Drug therapy, combination; Hemorheology; Prognosis","PeriodicalId":10226,"journal":{"name":"Chinese Journal of Primary Medicine and Pharmacy","volume":"27 1","pages":"563-567"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45445771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：